Galderma Announces Nemolizumab Data at American Academy of Dermatology (AAD) Annual Meeting

TOKYO, March 11, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release regarding presentation of the results up to 52 weeks from an interim analysis of the OLYMPIA open-label extension study of nemolizumab in patients with prurigo nodularis, and results from an analysis of two phase III studies (ARCADIA 1 and ARCADIA 2) of nemolizumab at 48 weeks in patients with moderate to severe atopic dermatitis, at American Academy of Dermatology (AAD) Annual Meeting. Nemolizumab is a humanized anti-human IL-31 receptor A monoclonal antibody created by Chugai. Clinical development of nemolizumab outside Japan is being conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis https://www.galderma.com/news/galderma-aad-2024-new-data-demonstrate-long-term-efficacy-nemolizumab-prurigo-nodularis-and

The release as fetched from its publisher. chugai-pharm.co.jp ↗